# CD20 in large B-cell lymphoma

2 EU-approved indications in large B-cell lymphoma need a CD20 result: rituximab (any line) and rituximab (1st line, advanced).

## Approved indications

### CD20-positive

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Rituximab](https://oncolabels.com/drugs/rituximab) (MabThera) | CD20-positive | + chemotherapy | 1st line, advanced | DLBCL only; Children and adolescents only; Aged 6 months to less than 18 years old |
| [Rituximab](https://oncolabels.com/drugs/rituximab) (MabThera) | CD20-positive | + CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) | Any line | DLBCL only |

## Label wording

- **Rituximab** (MabThera), Large B-cell lymphoma, any line: “MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf)
- **Rituximab** (MabThera), Large B-cell lymphoma, 1st line, advanced: “MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/large-b-cell-lymphoma/cd20